Semaglutide Long-Term Safety
3 articles in this topic.
Semaglutide Long-Term Safety
Tirzepatide Side Effects: What Dual Agonism Means
Tirzepatide's dual GIP/GLP-1 mechanism produces GI side effects in 20-33% of patients, mostly mild. Here's the full safety data from SURPASS and SURMOUNT.
13 min read|Mar 25, 2026
Semaglutide Long-Term Safety
GLP-1 Agonist Adverse Events: What Systematic Reviews Show
GLP-1 receptor agonist side effects from systematic reviews and meta-analyses: GI events, gallbladder disease, pancreatic, thyroid, and psychiatric safety data.
14 min read|Mar 22, 2026
Semaglutide Long-Term Safety
GLP-1 Agonists and Thyroid Cancer Risk
Do GLP-1 receptor agonists cause thyroid cancer? The rodent C-cell signal, human epidemiological data, FDA boxed warning, and what the evidence shows.
13 min read|Mar 22, 2026